| Prev Close | 0.00 |
| Day Low/High | 0.00 / 0.00 |
| 52 Wk Low/High | 0.00 / 0.00 |
| Exchange | NYSE |
| Div & Yield | N.A. (N.A) |
Latest News
New Lifetime High For Hospira (HSP)
Trade-Ideas LLC identified Hospira (HSP) as a new lifetime high candidate
Hospira (HSP) Showing Signs Of Being Strong And Under The Radar
Trade-Ideas LLC identified Hospira (HSP) as a strong and under the radar candidate
Trade-Ideas: Hospira (HSP) Is Today's New Lifetime High Stock
Trade-Ideas LLC identified Hospira (HSP) as a new lifetime high candidate
10 Best S&P 500 Health Care Stocks
So far in 2015, the health care sector has been outpacing the general market.
10 Best S&P 500 Stocks This Year
Stocks were rattled this week by Greece's impending default, causing the S&P 500 barely eek out a gain for the first half of the year. Netflix's stock has nearly doubled.
How Apple, Google and 7 Other Cash-Hoarding Companies Will Spend Their Billions
It's no secret companies like Apple, Google and Pfizer are sitting on piles of cash. The question is what they plan to do with all that money.
Hospira (HSP) Is Water-Logged And Getting Wetter Today
Trade-Ideas LLC identified Hospira (HSP) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
The 10 Biggest U.S. M&A Deals in 2015
Health care deals dominate the list of big mergers so far this year, while tech comes in second.
New Results From First Real-world Study Show Comparable Effectiveness And Safety Of Hospira's Inflectra™ (infliximab) In Patients With Rheumatic Diseases Switched From Reference Infliximab, Remicade™
- The new independent clinical study data presented at EULAR's annual congress this week adds to the growing wealth of data for Hospira's Inflectra (infliximab), the first biosimilar monoclonal antibody, which received approval from the European Commission in 2013
ANVISA Approves First Infliximab Biosimilar In Brazil
- Remsima™(infliximab) is the first biological medication approved by Brazil's regulator based on comparability
New Lifetime High For Hospira (HSP)
Trade-Ideas LLC identified Hospira (HSP) as a new lifetime high candidate
Hospira Shareholders Approve Merger Of Hospira And Pfizer At Special Meeting
Subject to certain closing conditions, Pfizer will acquire Hospira for $90 per share
Trade-Ideas: Hospira (HSP) Is Today's "Barbarian At The Gate" Stock
Trade-Ideas LLC identified Hospira (HSP) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
Antitrust Protections Hardly Provide a 'Road Map' for Merger Challenges, Regulators Say
It's a myth that regulators rely on covenants allocating antitrust risk for merger investigations; such agreements hardly play a role in the government analysis of a competition threat, regulators say.
When Should You Sell Your Kraft, Alcatel or Hospira Stock?
On the heels of Nokia's proposed Alcatel Lucent purchase, here's a closer look at what to do with a stock after a M&A, regardless of whether you already own it.
First-Quarter Deals Near $1 Trillion Mark Highest Value Since 2007
Mega deals from strategic players across a variety of industries pushed first-quarter deals to the highest value since 2007.
Hospira (HSP) Is Water-Logged And Getting Wetter Today
Trade-Ideas LLC identified Hospira (HSP) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
These 10 Pharma and Health Care Stocks Were the Best S&P 500 Performers Last Quarter
Health care is a hot investment sector, but some of the industry's best performers last quarter included well-known big benefits companies.
These 10 S&P 500 Stocks Were the Best Performers in the First Quarter
What do Kohl's, First Solar and Kraft Foods have in common? They are among the best performing stocks in 2015.
Jim Cramer's 'Mad Money' Recap: My Best and Worst of the First Quarter
This market is leaving a bad taste in the mouths of many investors, Cramer says.
Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen
-- Data presented at the National Kidney Foundation (NKF) Spring Meeting; single and multiple-dose pharmacokinetic and pharmacodynamic (PK/PD) studies support biosimilar application for Epoetin Hospira in the United States --
Valeant Boosts Offer for Salix to $15.8 Billion, Endo Drops Bid
Valeant comes out on top, following a competing bid from Endo International for the gastrointestinal drugmaker Salix.